Clinical Trial Update: Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1 [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating perioperative cemiplimab for patients with resectable non-small cell lung cancer and high PD-L1 expression. The study sta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Libtayo (cemiplimab)

Snippet

Sponsor: Henry Ford Health System | Conditions: Lung Cancer (NSCLC) | Phase 2 | Status: NOT_YET_RECRUITING